Willis Towers Watson's shares have fallen about 20% over the past year amid concerns about AI disrupting its business. However, its specialized insurance broking and consulting services are less vulnerable to AI than more commoditized segments, and AI is also boosting its internal productivity. The company reported modest 3% organic growth in Q1 but strong 19% earnings per share growth and expanding margins, aided by share buybacks and cost efficiencies. With a solid balance sheet, a 7% free cash flow yield, and a fair value estimate of $300–320, the stock is expected to deliver around 12% long-term returns, making it a buy despite recent challenges.
DBV Technologies has begun screening the first participant in its phase 2 THRIVE clinical trial to test the VIASKIN Peanut patch on infants aged 6 to 12 months with peanut allergies. The study aims to evaluate the patch's safety and effectiveness in ...
TETRA Technologies announced a public offering of 10,810,811 common shares priced at $9.25 each, aiming to raise funds for general corporate purposes, including part of the construction costs for its Arkansas bromine project. The offering includes a ...
Cryptocurrency markets experienced a significant downturn, with Bitcoin falling about 6.8% to $66,018 and Ethereum dropping over 8% to $1,835. Major altcoins like Binance Coin, Solana, and Dogecoin also saw declines of 6-9%. This broad sell-off refle...
Robbins LLP is investigating Beta Bionics, Inc.'s officers and directors for potential violations of securities laws and breaches of fiduciary duties following the company's announcement of weaker-than-expected patient growth. Beta Bionics reported a...
The U.S. Trade Representative has proposed tariffs of up to 12.5% on imports from 60 countries, including major economies like China, the EU, and Japan, due to their failure to ban goods made with forced labor. This move aims to level the playing fie...
